Psilocybin formulation Modulates Anxiety-Like Behaviour in Rat Autism Model VANCOUVER, BC, March 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders, is pleased to announce, it has found early indications…


Previous articleHorizons ETFs Completes Rebalance of World’s First Psychedelics ETF
Next articleSenior Program Director